On Wednesday 5 February, 2025, Teltow, Germany – The EU-funded micro2MACRO (m2M) project, which launched in December 2024, is set to advance tissue regeneration through a groundbreaking bioprinting platform.
m2M has a clear goal of precisely patterning cell aggregates and microtissues into stable, customizable grafts that can remodel into fully functional tissues after implantation. The project brings together top academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.
“We are honored to be a partner in the m2M project and have great confidence in its ability to significantly advance the development of therapies for tissue regeneration. We are excited to contribute our expertise, gained from over 30 years of experience in the field of regenerative medicine, as well as our regulatory knowledge as the holder of an EU-approved cell-based therapy for cartilage repair,” stated Dr. Giulietta Roël, Executive Director of CO.DON GmbH.
Aside from technical progress, m2M will also facilitate knowledge exchange and workshops to enhance the skills of researchers and healthcare professionals across Europe.
For more information on the research project and its funding, please visit the LinkedIn page of the project and the official website.
CO.DON GmbH, a company focused on developing, producing, and distributing autologous cell therapies for repairing cartilage defects, is currently marketing a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint, using only the patient’s own cartilage cells. Over 20,000 patients have already been successfully treated with CO.DON’s method. In January 2023, CO.DON GmbH was acquired by ReLive Biotechnologies, a global company based in the United States.
The Managing Director of CO.DON, Dr. Ying Zhou, leads the company with a strong vision and drive for innovation.
For more information, please visit www.codon.de and www.relivebio.com.
Media Contact:
Matthias Meißner
Director of Corporate Communications
Phone: +49 (0)341 99190 330
E-mail: pr@codon.de
This news release was distributed by https://pressat.co.uk/.
